Navigation Links
Palatin Announces Strategic Realignment of Operations
Date:9/24/2010

anotide for female sexual dysfunction (FSD): We are submitting protocols and a meeting request to the FDA for initiation of a Phase 2 clinical trial of subcutaneously administered bremelanotide for women with FSD, and anticipate that the meeting will be held late in the fourth quarter of calendar 2010 or early in the first quarter of calendar 2011. Assuming concurrence of the FDA, and depending on financial resources, this Phase 2 clinical trial for women with FSD could start as early as the first half of calendar 2011.

New peptides for sexual dysfunction: We intend to advance one or more of the peptides we have developed to preclinical toxicology and other studies required by the FDA prior to initiating human clinical trials.

Asthma

PL-3994 for acute severe asthma: We have planned a proof-of-concept human trial for asthma using a subcutaneously administered formulation of PL-3994, and will submit an Investigational New Drug application to the FDA in the fourth quarter of calendar 2010 for this trial. We also have an inhalation formulation of PL-3994 under development. Depending on financial resources, either or both the proof-of-concept human trial and preclinical inhalation toxicity studies could start as early as the first quarter of calendar 2011.

Obesity

Active work by Palatin under the collaboration portion of its research collaboration and license agreement with AstraZeneca concluded in January 2010, but we are still providing certain clinical trial related and other services to AstraZeneca. We are eligible for milestone payments totaling up to $145 million, with up to $85 million contingent upon development and regulatory milestones and the balance on achievement of sales targets, plus royalties on sales of approved products. AstraZeneca has responsibility for product commercialization, product discovery and development costs.

Realignment and Workforce Reductions'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
2. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
3. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
5. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
6. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
7. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
8. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
9. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
10. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
11. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... BioMed Realty Trust, Inc.,(NYSE: BMR ) ... underwriter,exercised its over-allotment option in full to purchase ... with BioMed,s previously,announced offering that priced on October ... of common stock, raising net proceeds of,approximately $212.4 ...
... a new dietary supplement resulting from years of, study by ... ... Del-Immune V, BOULDER, Colo., Oct. 6 On Thursday, October ... V(R) induction and its impact on cytotoxicity of,natural killer cells" will be ...
... European authority on natural/ organic certification -, ... /PRNewswire-FirstCall/ - Botaneco Specialty Ingredients,Inc. (Botaneco), a subsidiary ... second generation oleosome product, Hydresia(TM) G2, has,been authorized ... with,the standards for ecological and organic cosmetics. ECOCERT(R) ...
Cached Biology Technology:BioMed Realty Trust Announces Exercise of Over-Allotment Option 2BioMed Realty Trust Announces Exercise of Over-Allotment Option 3EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 3
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... neurodegenerative diseases, such as mad cow disease or its ... infectious protein called a prion. Remarkably, in recent years ... roles in biology, and prions even may act as ... But although prions have received a great deal of ...
... responsible for genital warts was on target at the halfway ... Frazer and trial manager, sexual health specialist Dr David Jardine ... have taken part in the trial so far run from ... has so far proven safe, and we want to know ...
... Bae, Ph.D., Postdoctoral Research Associate in the Baumann ... the way cells protect chromosome ends from misguided ... Molecular Cell, their paper entitled "A RAP1/TRF2 Complex ... Ends" employed a biochemical assay for double-strand break ...
Cached Biology News:Scientists identify prion's infectious secret 2Scientists identify prion's infectious secret 3Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
... Pierce ready-to-use 2-D gel marker mix was designed ... gel marker mix contains a complement of seven ... of value to those who use markers to ... molecular weight values of proteins undergoing 2-D separation ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
... Engine Tetrad thermal cycler expands the ... PTC-200 DNA Engine cycler. ... with a footprint only twice the ... laboratories that run massive quantities of ...
Biology Products: